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ABSTRACT   Biomaterial-related infection of joint 
replacements is the second most common cause of 
implant failure, with serious consequences. Chroni-
cally infected replacements cannot be treated without 
removal of the implant, as the bioﬁlm mode of growth 
protects the bacteria against antibiotics. This review dis-
cusses bioﬁlm formation on joint replacements and the 
important clinical phenomenon of small-colony variants 
(SCVs). These slow-growing phenotypic variants often 
remain undetected or are misdiagnosed using hospital 
microbiological analyses due to their unusual morpho-
logical appearance and biochemical reactions. In addi-
tion, SCVs make the infection difﬁcult to eradicate. 
They often lead to recurrence since they respond poorly 
to standard antibiotic treatment and can sometimes sur-
vive intracellularly.
■
In the USA alone, 250,000 hip replacements and 
400,000 knee replacements are done every year 
(Kurtz et al. 2005). These numbers are expected 
to double before the year 2030 because of the gen-
eral increase in average age globally and growing 
demands for a higher quality of life. 
As with all other biomaterials in humans, the use 
of joint replacements bears the risk of attracting 
infectious microorganisms. There are several theo-
ries on how infections of joint prostheses develop. 
Most studies on the interaction of the prosthesis 
with infecting organisms have shown that bac-
teria readily attach to devices during implanta-
tion (Lidwell et al. 1983). The main sources of 
contamination are the patient’s skin and airborne 
particles from theater personnel (Pittet and Ducel 
1994). The adhesion of bacteria itself is a compli-
cated process. All biomaterials undergo changes 
at the surface after implantation. The earliest and 
probably clinically most important step is the “race 
for the surface”, a contest between tissue cell inte-
gration and bacterial adhesion to that same surface 
(Gristina 1987). On contact, body ﬂuids immedi-
ately coat all surfaces with a layer of host material, 
mainly plasma proteins and platelets. These host 
proteins promote attachment of bacteria onto the 
implant by speciﬁc receptors and by non-speciﬁc 
mechanisms that may depend on their chemical 
composition, their hydrophobicity, and the charge 
of the implant surface (Bos et al. 1999). After 
their adhesion, the bacteria encase themselves in 
a hydrated matrix of polysaccharides and proteins 
(Costerton et al. 1999) to form a slimy layer known 
as a bioﬁlm (Figure 1). 
Bacteria within this protective bioﬁlm can 
remain “dormant” on the surface of a prosthesis for 
a long time; however, when the environmental cir-
cumstances change—such as reduced host immune 
function—bioﬁlm bacteria can cause a clinical 
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infection. Generally speaking, bioﬁlm infections 
will not clear until the implant has been removed 
and the patient must then be given antibiotic ther-
apy. This treatment can prolong the patient’s stay 
in hospital by several weeks, and additional sur-
gery may be required. Infection is thus a devastat-
ing complication from the point of view of both the 
patient and society, as it is associated with a sub-
stantial increase in morbidity and adds signiﬁcant 
costs to the healthcare system. 
The infection rate from joint replacements has 
dropped dramatically since the procedure was ﬁrst 
performed in the late 1960s, but even so about 1% 
of all patients develop such an infection (Josefs-
son and Kolmert 1993, Philips and Crane 2006). 
This percentage may seem small, but since these 
joint replacement operations are so common, it is 
a complication that affects a signiﬁcant number of 
patients. Moreover, bioﬁlm infections can cause 
severe problems, ranging from disfunctioning of 
the implanted device to lethal sepsis. Furthermore, 
treatment of bioﬁlm infections is complicated, as 
bioﬁlms offer enhanced protection for the infect-
ing organisms against the natural host defenses and 
antibiotic therapy (Gristina and Costerton 1985). 
Bacteria in a bioﬁlm are able to resist higher anti-
biotic concentrations than planktonic bacteria. In 
general, bacteria in a bioﬁlm are 10–1,000 times 
more resistant to antibiotics than their planktonic 
counterparts (Widmer 2001, Mah et al. 2003). 
Also, some bacteria (such as Staphylococcus 
aureus) form small-colony variants, characterized 
by reduced growth rate, resistance to aminoglyco-
sides, and possible intracellular persistence (Proc-
tor and Peters 1998). 
In this review we ﬁrst summarize current knowl-
edge regarding the formation of an infectious bio-
ﬁlm on orthopedic implants, and the mechanisms 
used by infectious organisms to cause a deep and 
chronic infection. We pay special attention to the 
role of strains resulting from a modiﬁcation of bac-
terial phenotype, so-called small-colony variants 
(SCVs), in bioﬁlms. Finally we review the failures 
in diagnosis and treatment in orthopedic surgery 
caused by SCVs, including possible clinical con-
sequences. 
Small-colony variants (SCVs) 
The pathogenesis of many orthopedic infections is 
related to the presence of microorganisms in bio-
ﬁlms. Bacteria that attach to a surface and grow as 
a bioﬁlm are protected from the killing action of 
antibiotics. The protective mechanisms at work in 
bioﬁlms appear to be distinct from those that are 
responsible for conventional antibiotic resistance 
(Gracia et al. 1997, Sheldon 2005). The bioﬁlm can 
act as a shield for the bacteria, making it difﬁcult 
for them to be reached and destroyed by antibiotic 
drugs. Two main mechanisms have been proposed 
to explain how bacteria in bioﬁlms become resis-
tant: (1) antibiotics do not reach bacteria present 
in the deeper layers of bioﬁlms because of the dif-
ﬁculty in penetrating the exopolysaccharide gel 
(slime), and (2) bacteria in deeper layers may be 
in a metabolic state that makes them less suscep-
tible to antibiotics (Costerton et al. 1987). Arciola 
et al. (2005) found that exopolysaccharide-produc-
ing bacterial strains showed a signiﬁcantly higher 
occurrence of antibiotic resistance than those 
strains that did not produce exopolysaccharides. 
This may explain why only one-third of prosthetic 
joint infections caused by slime-positive organisms 
can be successfully treated with antibiotics, while 
all infections caused by slime-negative organisms 
can be cured by antibiotic therapy (Davenport et 
al. 1986). 
Although bacteria in bioﬁlms are surrounded by 
an exopolysaccharide matrix that can restrict the 
Figure 1. Confocal laser scanning microscope overlay 
image of a 4-day-old Staphylococcus aureus bioﬁlm on 
polyethylene. The sample was stained with a live/dead 
stain (green/red) and with Calcoﬂuor white (blue) for slime 
staining. The bar represents 10 µm. 
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diffusion of antibiotics, this may not be the central 
reason for bioﬁlm-related antibiotic resistance. Jef-
ferson et al. (2005) showed that the antibiotic van-
comycin can fully penetrate the bioﬁlm but the dif-
fusion rate in a bioﬁlm is signiﬁcantly reduced as 
compared to in water. This suggests that whereas 
planktonic bacteria are quickly exposed to a high 
concentration of antibiotics, bacteria in the deeper 
layers of the bioﬁlm are exposed to a gradually 
increasing antibiotic concentration. Darouiche et 
al. (1994) showed good penetration of bioﬁlms 
by vancomycin, but that the resident bacteria were 
resistant. Likewise, rifampin has been found to 
penetrate bioﬁlms formed by Staphylococcus epi-
dermidis but fails to kill the bacteria effectively 
(Zheng and Stewart 2002). These studies indicate 
that even though the bioﬁlm is not a physical bar-
rier, it somehow does cause antibiotic resistance.
Based on their own results, Ashby et al. (1994) 
suggested that the growth rate of the bacteria in 
bioﬁlms plays a role in antibiotic resistance. The 
bacteria in a bioﬁlm do not grow exponentially; 
they are inﬂuenced by high cell densities (Fux et 
al. 2005) and are in a slow-growing or station-
ary phase (Costerton et al. 1999, Fux et al. 2005). 
However, not all bioﬁlm bacteria are resistant to 
antibiotics; most cells die after antibiotic therapy 
and only a small proportion of bacteria usually sur-
vive (Ashby et al. 1994, Muli and Struthers 1998). 
It has been suggested that some bacterial cells in 
the bioﬁlm develop a phenotype that renders them 
resistant to antibiotics (Cochran et al. 2000, Lewis 
2005) and that this development is triggered by 
environmental signals. The resistant cells are called 
persister cells (Stewart 2002, Lewis 2005). 
Bioﬁlm bacteria may produce persister cells that 
neither grow nor die in the presence of antibiotics 
(Cogan 2006). Persister cells are largely respon-
sible for the high levels of tolerance to antibiotics 
seen in bioﬁlms (Lewis 2005), but the environmen-
tal stimuli that turn on the switch to the persister 
phenotype are poorly understood. Keren et al. 
(2004) stated that production of Escherichia coli 
persisters depends on the phase of growth, since 
maintaining the E. coli culture at early exponen-
tial phase eliminated the persister cells. Similar 
dynamics were observed with Pseudomonas aeru-
ginosa and S. aureus (Keren et al. 2004). Using a 
mathematical model of bioﬁlm dynamics, Roberts 
and Stewart (2005) predicted that the number of 
persister cells increases in the bioﬁlm despite the 
fact that they are unable to grow, with accumula-
tion in regions of nutrient and oxygen depletion. 
In these regions, although normal cells are unable 
to grow, they slowly switch to the persister phe-
notype. Cogan (2006) suggested that expression 
of persister cells is controlled by the growth rate 
and the antibiotic concentration. Persister cells can 
be regarded as specialized survivor cells. After the 
antibiotic treatment has stopped, surviving persister 
cells are able to revert quickly to normal cells, thus 
allowing the bioﬁlm to grow again (Roberts and 
Stewart 2005). 
The clinical impact of an infection depends on 
the capacity of the infecting organisms to form a 
bioﬁlm and the ability of bacterial subpopulations 
to switch to the dormant metabolic state known as 
small-colony variants (SCVs). Although it is not 
known whether SCVs and persister cells express 
exactly the same set of genes, there are many 
similarities between SCVs and persister cells, 
especially regarding how both subpopulations are 
formed and their reduced sensitivity to antibiotics. 
Bayston (2000) hypothesized that the formation of 
SCVs takes place when the bioﬁlm is thick enough 
to serve as a barrier for oxygen and nutrients. Nutri-
ent and oxygen limitation causes some bacteria in 
the lower layers of the bioﬁlm to enter a non-grow-
ing or “dormant” state: the SCVs, in which they 
are less susceptible to growth-dependent antibiotic 
killing. 
Many infections in the developed world are 
caused by bioﬁlms, which has sparked renewed 
interest in SCVs. The clinical relevance of SCVs 
has been unclear for a long time. Many recent 
studies have shown that SCVs are largely respon-
sible for the recalcitrance of infections caused by 
bioﬁlms (von Eiff et al. 1997, 1999, Drenkard and 
Ausubel 2002, Seifert et al. 2003). The signiﬁ-
cance of SCVs as causative organisms in chronic 
and recurrent infections has been demonstrated in 
patients with chronic osteomyelitis (von Eiff et 
al. 1997) and cystic ﬁbrosis (Haussler et al. 1999, 
Drenkard and Ausubel 2002, Kiristis et al. 2005). 
In the treatment of chronic osteomyelitis with 
gentamicin-loaded bone cement beads, the slow 
release of gentamicin from the beads into the local 
environment is an efﬁcient way of selecting for 
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SCVs (von Eiff et al. 1997). In a study of S. aureus 
strains isolated from patients with osteomyelitis, 
SCVs were found in about 29% of the cases (von 
Eiff et al. 1997). Likewise, the occurrence of S. 
aureus SCVs is observed in patients with cystic 
ﬁbrosis (CF) after long-term antibiotic treatment 
(Kahl et al. 2003a). Analysis of sputum from  CF 
patients showed that more than two-thirds were 
chronically colonized by S. aureus, and half 
of these samples were found to contain SCVs 
(Kahl et al. 2003b). Also, P. aeruginosa appears 
to play a role in the CF lung and P. aeruginosa 
SCVs were isolated from one-third of NN patients 
with P. aeruginosa infected lungs (Haussler et al. 
1999). Recently, implant-related infections due to 
SCVs have been described, involving pacemakers 
(Seifert et al. 2003), ventriculoperitoneal shunts 
(Spanu et al. 2005), and hip replacements (Sendi 
et al. 2006). 
Characteristic features of SCVs 
The phenomenon of SCVs has been reported for 
several genera and species of bacteria, including 
the genera Staphylococcus (Figure 2) and Pseu-
domonas, and diverse species of Enterobacteria-
ceae (Bayer et al. 1987, Wise 1998, Costerton et 
al. 1999). Most SCVs isolated from clinical speci-
mens have been identiﬁed as S. aureus. SCVs share 
many characteristic features, but since the great-
est amount of information available relates to S. 
aureus, we have concentrated on S. aureus SCVs 
in this review. 
SCVs of S. aureus (Table) grow slowly and pro-
duce small colonies on standard media. These are 
10 times smaller than the usual S. aureus colonies 
(Bergoge-Berezin 2000). SCVs have the ability to 
revert to normal growth (Musher et al. 1977, Lewis 
et al. 1991) but there are no data available about 
the genetic events responsible for the reappearance 
of larger colonies. In addition, S. aureus SCVs 
are characterized as electron transport-deﬁcient 
bacteria because of their auxotrophism to hemin 
Figure 2. Sheep blood agar plates (panels A and B) and 
magniﬁed sectors (panels C and D) after overnight incuba-
tion at 37°C, showing two morphotypes of clonal isolates of 
Staphylococcus lugdunensis recovered from blood culture-
sand the infected pocket of a patient with pacemaker infec-
tion. Panels A and C show S. lugdunensis with the normal 
phenotype, characterized by colonies with yellow pigmen-
tation and weak hemolysis. Panels B and D show small 
colony variants, characterized by tiny (pinpoint) non-pig-
mented, non-hemolytic colonies. The pictures in this ﬁgure 
were taken with permission from Seifert H, Oltmanns D, 
Becker K, Wisplinghoff H, von Eiff C. Staphylococcus lug-
dunensis pacemaker-related infection. Emerg Infect Dis 
2005 Aug;11(8):1283-6. Available from http://www.cdc.
gov/ncidod/EID/vol11no08/04-1177.htm.
Table 1. Differences in features between S. aureus and its SCVs 
 Normal colonies Small colony  References
 of S. aureus variants of
   S. aureus
   
Colony size (approx.)  2 mm 0.2 mm Bergoge-Berezin 2000, Roggenkamp et al. 1998
Coagulase production  Yes No Seifert et al. 2003
Hemolytic Yes No Balwit et al. 1994
Pigment  Yes No Balwit et al. 1994, Proctor et al. 1998
Auxotrophism, hemin  
  and/or menadion No Yes Kahl et al. 2003, Proctor and Peters 1998
Sensitivity to amino-
  glycoside antibiotics Sensitive Resistant Rusthoven et al. 1979, Proctor and Peters 1998
Intracellular survival  No Yes Kahl et al. 1998, Vaudaux et al. 2002, von Eiff et al. 2001
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or menadione. Hemin/menadione auxotrophy is 
the inability of an organism to synthesize hemin 
or menadione, which is required for its growth. 
Hemin or menadione auxotrophs will therefore 
only be able to grow if hemin or menadione can 
be taken up from the environment. Consequently, 
these SCVs produce very small, mostly non-pig-
mented, and non-hemolytic colonies on normal 
agar plates. Moreover, they show various other 
features that are atypical of  S. aureus, includ-
ing reduced coagulase production and increased 
resistance to aminoglycosides and cell wall-active 
antibiotics (von Eiff et al. 1997, Proctor and Peters 
1998, Proctor et al. 1998, Kahl et al. 1998, 2003a, 
Seifert et al. 1999, Baumert et al. 2002). Further-
more, the ability of these variants to persist intra-
cellularly within non-professional phagocytes, 
cells other than macrophages and neutrophils, has 
been described (Kahl et al. 1998, von Eiff et al. 
2001, Vaudaux et al. 2002).  S. aureus SCVs are 
capable of living intracellularly and consequently 
survive antibiotic therapy because they produce 
reduced levels of α-toxin, which prevents the cells 
from lysing (von Eiff et al. 2000). 
Failure to diagnose bioﬁlm infections in ortho-
pedics 
Infection after joint replacement can present a diag-
nostic challenge, especially in late-onset infection, 
as the patient’s pain may mimic that experienced 
from other common complications of the surgery. 
There are no preoperative tests that are consistently 
sensitive and speciﬁc for infection in patients who 
need revision surgery. Deﬁnitive diagnosis based 
solely on history and physical ﬁndings may prove 
inaccurate. The only consistent clinical ﬁnding in 
bioﬁlm infections is pain at the site of the implant. 
However, patients with early onset of their infec-
tion typically have pain, redness, and swelling 
at the joint, or drainage from the wound, while 
patients who develop infections later in recovery 
complain of a gradual onset of joint pain—often 
without fever or other obvious signs of joint infec-
tion. There are less clinical signs and symptoms of 
infection in those patients. Hematological testing, 
radiographs and bone scans are highly variable, 
and all may give positive results in both aseptic 
loosening and infection, making these indicators of 
limited use. In addition, the sensitivity of preopera-
tive aspiration of the infected joint does not exceed 
75% (Barrack et al. 1997). Only the sum of clinical 
signs and symptoms, blood tests, radiography, and 
a microbiological workup can provide an accurate 
diagnosis. Investigation of suspected infection in 
prosthetic joint replacements remains a difﬁcult 
orthopedic problem, with important therapeutic 
implications. It is extremely important to be able 
to differentiate aseptic loosening from infection, as 
the treatment of these two is totally different.
Auxotrophism 
Intraoperative specimens provide the most accu-
rate samples for microbiological culture and 
are frequently used as the reference standard for 
diagnosing infected joint replacements. However, 
standard microbiological culture techniques are 
only moderately sensitive and speciﬁc in diagnos-
ing infected arthroplasties. A very low inoculum, 
adherent bacteria, and the existence of SCVs may 
limit detection. Consequently, a signiﬁcant pro-
portion of these infections is probably never rec-
ognized (Philips and Kattapuram 1983, Tunney et 
al. 1998, Costerton et al. 1999, Neut et al. 2003). 
The incidence of infection in joint prostheses may 
therefore be grossly underestimated, and hypothet-
ically it might be argued that inadequate microbial 
sampling by current hospital diagnostic methods 
is at least partially responsible for the high failure 
rates in revision surgery. Adequate sampling is 
extremely important in clinical practice—as, for 
example, septic joint prostheses require eradica-
tion of the infecting bacteria before implantation 
of a new prosthesis, whereas uninfected joint pros-
theses can be replaced immediately.
Although microscopic morphology and cell 
size, and Gram staining of SCVs may be normal 
(Haussler et al. 1999, Looney 2000), clinical micro-
biology laboratories may fail to detect them. Since 
these phenotypic variants have a low metabolism 
and grow very slowly on standard agar plates, they 
can easily be missed in a routine laboratory, where 
tissue samples are cultured for only 48 h. Colony 
formation by SCVs can often be detected on cul-
ture media after 48–72 h of culture during primary 
isolation (Proctor et al. 1995, Roggenkamp et al. 
1998). Neut et al. (2003) showed that prolonging 
the culture period of microbiological samples from 
infected joint prostheses could double the detection 
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rate for infections, as bacteria in bioﬁlms generally 
require a longer time in culture (Atkins and Bowler 
1998). As  S. aureus SCVs show generation times 
of up to 6 times longer than that for metabolically 
normal  S. aureus (Proctor et al. 1995), cultures for 
detection of SCVs should be incubated for at least 
6 days (Looney 2000). The addition of hemin and 
menadion to routine blood agar used for hospital 
culture increases the detection rate, as SCVs form 
normal-sized colonies and grow at the same speed 
as the parent strain on agar plates enriched with 
hemin and menadione (Kahl et al. 2003a). SCVs 
cultured from patients with persistent and relaps-
ing infections have been shown to be auxotrophic 
for hemin and/or menadion (Proctor and Peters 
1998). Supplementation of the auxotrophs with 
exogenous menadione or hemin resulted in normal 
growth and morphology, and increased hemolytic 
activity (Balwit et al. 1994). Subcultivation of 
SCVs showed hemin-dependent growth: formation 
of larger colonies (diameter 2 mm) in the presence 
of hemin and formation of small colonies (diameter 
0.2 mm) in its absence (Roggenkamp et al. 1998). 
Because of their particular growth character-
istics, atypical morphological appearance, and 
unusual biochemical reactions (e.g. reduced toxin 
production), SCVs present a challenge to the clini-
cal microbiologist, often resulting in misidentiﬁca-
tion (Proctor et al. 1995, 1998, Proctor and Peters 
1998). For example, Seifert et al. (2003) described 
case studies in which blood cultures yielded non-
pigmented and non-hemolytic staphylococci, 
which were initially identiﬁed as coagulase-nega-
tive staphylococci on the basis of a negative tube 
coagulation test and the API ID 32 Staph system. 
However, the morphological appearance of colo-
nies was suggestive of SCVs of  S. aureus,  and 
this was conﬁrmed by DNA ampliﬁcation using 
the polymerase chain reaction (PCR). Likewise, 
using molecular methods, Spanu et al. (2005) iden-
tiﬁed  S. aureus SCVs that were methicillin-resis-
tant, while these had originally been identiﬁed by 
3 widely used automated identiﬁcation systems as 
being methicillin-susceptible coagulase-negative 
staphylococci. Thus, it is most important to take 
SCVs into account as a possible cause of persistent 
infectious diseases, particularly when no bacteria 
or unusual microorganisms can be found in speci-
mens from such cases.
Reduced production of virulence factors 
When there is a suspicion of an infected joint 
prosthesis, biochemical investigations can be per-
formed. Erythrocyte sediment rate (ESR) and C-
reactive protein (CRP) levels are important labora-
tory parameters in the diagnosis of postoperative 
infection in patients. In joint prosthesis infections 
caused by bacteria of high virulence, high CRP and 
ESR values are common (Shih et al. 1987, Sanzén 
and Carlsson 1989), but in low-grade infections 
the absence of elevated levels of these two param-
eters does not exclude the possibility of a bioﬁlm 
infection. Most recent studies tend to favor CRP 
over ESR, mainly because of the fact that ESR 
is affected by a multitude of factors (Ng 1998). 
CRP levels rise early and before the onset of clini-
cal symptoms, and decline with the resolution of 
infection. Cytokines, particularly IL-6, induce syn-
thesis of CRP in the liver (Kragsbjerg and Holm-
berg 1995). As part of their general reduction in 
metabolic activity,  S. aureus SCVs do not produce 
virulence factors such as α-toxin, coagulase, or 
other products that are associated with stimulation 
of cytokine release and immune response (Bayston 
2000). Limited release of cytokines at the site of an 
infection with SCVs does not cause elevated levels 
of CRP. Thus, measurement of the CRP level is not 
an adequate diagnostic tool when establishing that 
there is a postoperative infection caused by SCVs. 
Failure in treatment of bioﬁlm infections in 
orthopedics 
Treatment of infected joint replacements is dif-
ﬁcult, and usually requires appropriate surgical 
intervention combined with a prolonged course of 
antibiotic therapy. The choice of optimal manage-
ment depends on the duration and pathogenesis of 
the infection, stability of the implant, antibiotic sus-
ceptibility of the pathogen, and condition of the soft 
tissue. To eradicate chronic prosthesis infection, 
most authors recommend removal of the implant 
(McDonald et al. 1989, Tattevin et al. 1999) and 
two-stage revision surgery. Prior to a successful 
reimplantation after infection, the infection should 
be fully eradicated through surgical debridement 
and removal of the prosthesis. Subsequently, high 
local levels of antibiotics can be achieved in the 
compromised tissue by implantation of chains of 
gentamicin-loaded bone cement beads, before a 
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second prosthesis is actually implanted. The gen-
tamicin concentration that can be achieved in this 
way is much higher than with systemic administra-
tion (Walenkamp 1997). These beads are usually 
removed after 2 weeks and the absence of cultiva-
ble microorganisms in excised soft tissue samples 
by routine hospital culture is taken as a sign that the 
infection has been eradicated, and implantation of 
a new prosthesis can take place. Although the use 
of gentamicin-loaded beads is accepted in clinical 
practice, the beads themselves can act as a bioma-
terial surface to which subpopulations of bacteria 
may preferentially adhere, grow and possibly even 
develop antibiotic resistance (Neut et al. 2001).
The slow release of gentamicin from the beads 
into the local environment is an efﬁcient way of 
selecting for SCVs (von Eiff et al. 1997). In rou-
tine hospital culture, such minority populations are 
disregarded, but their presence may have conse-
quences in the subsequent treatment of a patient 
after orthopedic revision surgery. Neglecting SCVs 
will contribute to the occurrence of reinfections 
after employing gentamicin-loaded beads, and this 
may be one of the reasons for higher infection rates 
after revision surgery. 
Antibiotic resistance 
Bacteria persisting as SCVs within bioﬁlms may 
explain the recurrent nature of bioﬁlm infections. 
SCVs cause persistent and relapsing infections 
due to their increased resistance to antibiotics. 
The depressed electron transport activity seen in 
these auxotrophic SCVs may account for their in 
vitro resistance to a variety of antibiotics (Proctor 
and Peters 1998). In addition, SCVs have defec-
tive catalase activity, which may interfere with 
oxidative metabolism and aminoglycoside uptake 
(Rusthoven et al. 1979). The low content of ATP in 
SCVs causes inefﬁcient transport of aminoglyco-
sides into the cell, resulting in increased resistance 
to gentamicin and other aminoglycosides (Proctor 
and Peters 1998). The minimum inhibitory concen-
trations of four aminoglycoside antibiotics were 
found to be 8- to over 16 times higher for SCVs 
than for the normal large colony type (Rusthoven 
et al. 1979). Moreover, the slow growth of SCVs 
and consequently cell-wall division reduces the 
effectiveness of antibiotics that act at the cell wall 
(Looney 2000). However, SCVs are susceptible to a 
range of antibiotics with other modes of action, the 
hydrophilic antibiotics tetracycline and erythromy-
cin for example, and to the hydrophobic antibiotics 
rifampicin and chloramphenicol (Langford et al. 
1989). For optimal eradication of SCVs, treatment 
should consist of therapy with an antibiotic that has 
optimal bactericidal activity against slowly grow-
ing bacteria (Vaudaux et al. 2006). Rifampin may 
be the most efﬁcient antibiotic because of its excel-
lent efﬁcacy against stationary and adherent bac-
teria (Widmer et al. 1990). Although rifampin has 
very good bactericidal activity against slow-grow-
ing bacteria, it should be given in combination with 
other antibiotics because of the rapid emergence of 
resistance when given alone (Vaudaux et al. 2006). 
The combination proposed by Sendi et al. (2006), 
rifampin with a ﬂuoroquinolone, has been shown 
to be successful when dealing with hip replace-
ments infected with S. aureus SCVs. 
Intracellular survival
S. aureus SCVs can survive inside non-profes-
sional phagocytes, such as endothelial cells and 
osteoblasts (Hudson et al. 1995, von Eiff et al. 
2000). These SCVs have a dampened produc-
tion of cytotoxins and this may downregulate the 
induction of cell lysis or apoptosis (Proctor et al. 
2006). Unlike the wild type, they do not kill the 
cells because they produce very little α-toxin (von 
Eiff et al. 2000). Their reduced virulence creates a 
completely new niche for these bacteria inside the 
host cell (Proctor 1994, Proctor et al. 1995). The 
intracellular location may shield these SCVs from 
the host defenses and exposure to antibiotics (Kahl 
et al. 1998, Vaudaux et al. 2002, von Eiff et al. 
2001), thus providing one explanation for the dif-
ﬁculty in clearing SCVs from host tissues. In addi-
tion,  S. aureus SCVs can also be phagocytosed by 
monocytes and macrophages. They can hide within 
these host cells, then revert to the highly virulent 
rapidly growing form and lyse the host cell once 
the host immune response has dropped and anti-
biotic therapy is complete (von Eiff et al. 2000). 
S. aureus persisting as SCVs inside host cells may 
also be an explanation for the recurrent nature of 
these bioﬁlm infections. 
Conclusions 
Clinical and laboratory ﬁndings lead to the con-
306 Acta Orthopaedica 2007; 78 (3): 299–308
clusion that SCVs must be actively sought after 
in clinical microbiology, because they grow very 
slowly and can easily be missed. Particularly those 
samples from patients who have undergone long-
term antibiotic therapy (e.g. antibiotic-loaded bone 
cement beads or spacers) or from  individuals suf-
fering from unusually persistent or recurrent infec-
tions should be examined meticulously for SCVs. 
In addition, it is most important to take SCVs into 
account as a possible cause of persistent infectious 
diseases when no bacteria or unusual microorgan-
isms are found in materials obtained from such 
cases. Also, due to reduced production of virulence 
factors by SCVs, absence of elevated levels of 
CRP in patients postoperatively does not exclude 
the possibility of a bioﬁlm infection. An optimal 
treatment of SCV-mediated infections has not 
been established, but these bacterial forms show 
increased resistance to aminoglycosides and cell-
wall active antibiotics. 
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